UCSF Helen Diller Family Comprehensive Cancer Center | Strategic Alliance Partners

October 13, 2023

State of the Science Summit - Bladder/Prostate Cancer: Chaired by Arpita Desai, MD and Rahul Aggarwal, MD

September 29, 2023

Ana Velázquez Mañana, MD, discusses findings from a study determining survivorship care needs in low-income, older patients with lung cancer.

September 28, 2023

Jacqueline Aredo, MD, MS, discusses findings from a study assessing the molecular distribution of driver mutations and tumor suppressor gene mutations in patients with non–small cell lung cancer who are eligible for lung cancer screening.

September 28, 2023

Andrew Ko, MD, FASCO, highlights what the potential approval of zolbetuximab could mean for the first-line treatment paradigm for patients with CLDN18.2-positive gastric/gastroesophageal junction adenocarcinoma and detailed other ongoing research in the gastrointestinal cancer space.

September 25, 2023

Ajai Chari, MD, director, discusses the safety profile of talquetamab following the drug’s FDA approval for patients with relapsed/refractory multiple myeloma.

September 22, 2023

Ajai Chari, MD, discusses selecting between CAR T-cell therapies and bispecific antibodies in multiple myeloma, expands on the factors that can help inform these decisions, and highlights the need for additional data to help inform sequencing and potential combinations for these therapies.

September 20, 2023

Ajai Chari, MD, discusses the evolving role of bispecific antibodies and CAR T-cell therapies, such as ciltacabtagene autoleucel, in the treatment of patients with multiple myeloma.

September 18, 2023

Ajai Chari, MD, director, discusses the current landscape of bispecific antibodies in relapsed/refractory multiple myeloma.

September 14, 2023

Ajai Chari, MD, discusses the use of the CAR T-cell therapies idecabtagene vicleucel and ciltacabtagene autoleucel in the treatment of patients with multiple myeloma.

September 13, 2023

Ajai Chari, MD, discusses important patient factors to consider when selecting between currently approved BCMA-targeted therapies for the treatment of patients with multiple myeloma.

August 31, 2023

Dr Kelley discusses standard first-line treatment options for patients with advanced HCC, key findings from the phase 3 HIMALAYA trial, and the safety profile of the STRIDE regimen in this population.

August 24, 2023

State of Science Summit: Chaired by Andrew Ko, MD, FASCO

August 18, 2023

Ajai Chari, MD, discusses how the FDA approval of talquetamab addresses several unmet needs in relapsed/refractory multiple myeloma and expands on the agent’s efficacy data and safety profile observed in MonumenTAL-1.

August 14, 2023

Ajai Chari, MD, discusses the significance of the FDA approval of talquetamab in patients with relapsed/refractory multiple myeloma.

August 10, 2023

Collin Blakely, MD, PhD, discusses a phase 2 trial evaluating the use of neoadjuvant osimertinib in patients with surgically resectable EGFR-mutated non-small cell lung cancer, findings from which were presented at the 2023 ASCO Annual Meeting.

August 10, 2023

Denise M. Wolf, PhD, discusses research into biomarkers predicting responses to immunotherapy in the phase 2 I-SPY2 trial in patients with early-stage breast cancer.

August 09, 2023

Ana I. Velazquez Manana, MD, MSc, discusses how systemic racism appears in oncology.

July 13, 2023

Responses achieved with enfortumab vedotin plus pembrolizumab were found to be rapid and durable in patients with previously untreated locally advanced or metastatic urothelial carcinoma who were cisplatin ineligible.

June 22, 2023

Dr Manana discusses how systemic racism appears in oncology practice, tools clinicians can use to learn about and address their implicit biases, and the importance of connecting patients with a multidisciplinary team to provide necessary resources and care.

June 15, 2023

The addition of gedatolisib to palbociclib and letrozole produced durable responses with comparable safety to that observed with palbociclib and letrozole alone in treatment-naïve patients with estrogen receptor-positive, HER2-negative advanced breast cancer.